How do you approach treatment selection between adjuvant pembrolizumab alone and pembrolizumab plus belzutifan in patients with clear cell renal cell carcinoma?

This is a very clinically relevant question given the recent approval of the combination. When facing a resected high-risk ccRCC patient, the first question is: what is the estimated risk of recurrence? Keep in mind that our current models are outdated, using features such as tumor size and grade, a...

The discussion of adjuvant therapy with patients following nephrectomy has gone from one of the simplest to one of the most complex over the last several years. The lack of benefit in the higher-risk groups on prespecified subgroup analyses in LITESPARK-022, along with immature survival data, adds t...